Adaptimmune Therapeutics PLC (ADAP)
1.12
+0.11
(+10.89%)
USD |
NASDAQ |
Apr 23, 16:00
1.15
+0.03
(+2.68%)
After-Hours: 20:00
Adaptimmune Therapeutics Enterprise Value: 129.51M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 129.51M |
| April 22, 2024 | 102.36M |
| April 19, 2024 | 94.14M |
| April 18, 2024 | 74.81M |
| April 17, 2024 | 96.68M |
| April 16, 2024 | 107.29M |
| April 15, 2024 | 112.23M |
| April 12, 2024 | 139.38M |
| April 11, 2024 | 171.47M |
| April 10, 2024 | 166.53M |
| April 09, 2024 | 191.21M |
| April 08, 2024 | 188.74M |
| April 05, 2024 | 191.21M |
| April 04, 2024 | 186.28M |
| April 03, 2024 | 193.68M |
| April 02, 2024 | 198.62M |
| April 01, 2024 | 215.89M |
| March 28, 2024 | 243.05M |
| March 27, 2024 | 243.05M |
| March 26, 2024 | 228.24M |
| March 25, 2024 | 208.49M |
| March 22, 2024 | 208.49M |
| March 21, 2024 | 183.81M |
| March 20, 2024 | 181.34M |
| March 19, 2024 | 201.09M |
| Date | Value |
|---|---|
| March 18, 2024 | 215.89M |
| March 15, 2024 | 218.36M |
| March 14, 2024 | 213.43M |
| March 13, 2024 | 245.51M |
| March 12, 2024 | 220.83M |
| March 11, 2024 | 233.17M |
| March 08, 2024 | 285.01M |
| March 07, 2024 | 282.54M |
| March 06, 2024 | 275.13M |
| March 05, 2024 | 213.43M |
| March 04, 2024 | 218.36M |
| March 01, 2024 | 214.26M |
| February 29, 2024 | 209.72M |
| February 28, 2024 | 218.80M |
| February 27, 2024 | 241.52M |
| February 26, 2024 | 225.62M |
| February 23, 2024 | 189.27M |
| February 22, 2024 | 166.55M |
| February 21, 2024 | 193.81M |
| February 20, 2024 | 139.29M |
| February 16, 2024 | 125.66M |
| February 15, 2024 | 137.02M |
| February 14, 2024 | 143.84M |
| February 13, 2024 | 124.53M |
| February 12, 2024 | 127.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-98.43M
Minimum
Mar 15 2022
1.554B
Maximum
Jun 04 2020
244.92M
Average
143.84M
Median
Feb 14 2024
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -4.063M |
| NuCana PLC | -13.49M |
| Autolus Therapeutics PLC | 951.78M |
| Mereo BioPharma Group PLC | 336.89M |
| TC BioPharm (Holdings) PLC | 1.911M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.92M |
| Revenue (Quarterly) | 0.231M |
| Total Expenses (Quarterly) | 50.09M |
| EPS Diluted (Quarterly) | -0.18 |
| Profit Margin (Quarterly) | -20.74K% |
| Earnings Yield | -42.30% |
| Normalized Earnings Yield | -50.37 |